Effectiveness and Adverse Effects of Risperidone in Children with Autism Spectrum Disorder in a Naturalistic Clinical Setting at a University Hospital in Oman

Table 2

Sex-specific changes in the body mass index of children with an autism spectrum disorder in the 12 months’ postinitiation of treatment with risperidone, as compared to baseline.

Sex	BMI factor	Mean (SD)	Paired t-test value
Male	BMI at the start of treatment	15.80 (2.42)	—
	BMI 12 months after treatment	16.43 (3.15)
	Change in BMI after 12 months of treatment	0.62 (1.57)	0.001
Female	BMI at the start of treatment	16.77 (3.63)	—
	BMI 12 months after treatment	16.97 (3.86)
	Change in BMI after 12 months of treatment	0.20 (2.83)	0.738

BMI body mass index. Bold indicates that value of is considered statistically significant.